Pfizer Inc. (PFE)
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
IP Group shares climb 9% on potential royalties from Pfizer's $7.3bn Metsera deal
Shares in IP Group PLC (LSE:IPO) rose 9% on Monday after investors welcomed the potential for future royalty income from Metsera, a biotech company that Pfizer has agreed to acquire for up to $7.3 billion. The agreement, announced in September, includes $4.9 billion in upfront cash and gives Pfizer control of Metsera's portfolio of next-generation obesity treatments.
IP Group in line for future royalties from Pfizer's drug deal
IP Group PLC (LSE:IPO) could see future royalty income from a new wave of obesity drugs being developed by Metsera, a biotech company that Pfizer Inc (NYSE:PFE, ETR:PFE) has agreed to buy for up to $7.3 billion. The deal, announced in late September, includes $4.9 billion in upfront cash and gives the US pharmaceutical giant control of a portfolio of next-generation obesity treatments.
4 Dividend Stocks to Double Up on Right Now -- Including United Parcel Service and Pfizer
Sometimes, things are going great for a stock with potentially more good news on the way. In other cases, things are going so badly for a stock that it almost has nowhere to go but up.
Here's Why Pfizer (PFE) Fell More Than Broader Market
In the latest trading session, Pfizer (PFE) closed at $25.24, marking a -1.71% move from the previous day.
Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings
Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
Pfizer Offers High Yield And Capital Appreciation Opportunities (Technical Analysis)
Pfizer surged 15% last week on positive news, including a direct-to-consumer deal and a three-year tariff reprieve. PFE offers a high 6.28% yield, with a forward PE of 8.87, and its dividend is considered safe by Seeking Alpha. Technical analysis shows PFE above its 30-week EMA, with bullish short- and long-term momentum and strong buying volume from institutional investors.
Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
After tanking in early August, the world's most valuable pharmaceutical stock has roared back with a vengeance. That firm is Eli Lilly and Company NYSE: LLY, the maker of the wildly popular weight loss and diabetes drugs Zepbound and Mounjaro.
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (October 2025)
Shares of Pfizer ( NYSE: PFE ) gained 10.02% over the past month after gaining 4.50% the month prior.
Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?
Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.
